Immunological evaluation of synthetic glycosylphosphatidylinositol glycoconjugates as vaccine candidates against malaria by Malik, A. et al.
Subscriber access provided by MPI FUR KOLLOID UND GRENZFLACH
is published by the American Chemical Society. 1155 Sixteenth Street N.W.,
Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the
course of their duties.
Article
Immunological Evaluation of Synthetic Glycosylphosphatidylinositol
Glycoconjugates as Vaccine Candidates Against Malaria
Ankita Malik, Fridolin Steinbeis, Maria Antonietta Carillo,
Peter H Seeberger, Bernd Lepenies, and Daniel Varon Silva
ACS Chem. Biol., Just Accepted Manuscript • DOI: 10.1021/acschembio.9b00739 • Publication Date (Web): 01 Oct 2019
Downloaded from pubs.acs.org on October 7, 2019
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a service to the research community to expedite the dissemination
of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in
full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully
peer reviewed, but should not be considered the official version of record. They are citable by the
Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore,
the “Just Accepted” Web site may not include all articles that will be published in the journal. After
a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web
site and published as an ASAP article. Note that technical editing may introduce minor changes
to the manuscript text and/or graphics which could affect content, and all legal disclaimers and
ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or
consequences arising from the use of information contained in these “Just Accepted” manuscripts.
1Immunological Evaluation of Synthetic 
Glycosylphosphatidylinositol Glycoconjugates as Vaccine 
Candidates Against Malaria
Ankita Malik,1,2,3,§ Fridolin Steinbeis,1,4,§ Maria Antonietta Carillo,1 Peter H. Seeberger,1,2 Bernd 
Lepenies1,2,5* and Daniel Varón Silva1,2*
1 Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 
1, 14476 Potsdam, Germany.
2 Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195 Berlin, Germany
3 Current address: Institute of Supramolecular Science and Engineering, Allée Gaspard Monge 8, 
Strasbourg FR 67083, France.
4 Current address: Department of Infectious Diseases and Respiratory Medicine, Charité – 
Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
5 Immunology Unit & Research Center for Emerging Infections and Zoonoses, University of Veterinary 
Medicine Hannover, Bünteweg 17, 30559 Hannover, Germany.
 § Contributed equally to this work
* Corresponding author(s)
Abstract
Glycosylphosphatidylinositols (GPIs) are complex glycolipids present on the surfaces of Plasmodium 
parasites that may act as toxins during the progression of malaria. GPIs can activate the immune system 
during infection and induce the formation of anti-GPI antibodies that neutralize their activity. Therefore, 
an anti-toxic vaccine based on GPI glycoconjugates may prevent malaria pathogenesis. To evaluate the 
role of three key modifications on Plasmodium GPI glycan in the activity of these glycolipids, we 
synthesized and investigated six structurally distinct GPI fragments from P. falciparum. The synthetic 
glycans were conjugated to the CRM197 carrier protein and were tested for immunogenicity and efficacy 
as antimalarial vaccine candidates in an experimental cerebral malaria (ECM) model using C57BL/6JRj 
mice. Protection may be dependent on both, the antibody and cellular immune response to GPIs, and 
the elicited immune response depends on the orientation of the glycan, the number of mannoses in the 
structure and the presence of the phosphoethanolamine and inositol units. This study provides insights 
into the epitopes in GPIs and contributes to the development of GPI-based anti-toxin vaccine candidates 
against cerebral malaria.
 Introduction
Malaria is a serious and fatal disease in humans 
caused by protozoan parasites of the genus 
Plasmodium and a major health threat in 
developing countries. Nearly half of the world's 
population is at risk of malaria infection, 
especially children and pregnant women in sub-
Saharan Africa.1 In 2017, 219 million cases of 
malaria and 435 000 deaths were reported.2 
Young children, elderly and immunosuppressed 
persons are at higher risk of cerebral malaria 
(CM), the most severe form of the disease, which 
is caused by P. falciparum and can lead to long-
term neurologic sequelae or death.3 The 
treatment of P. falciparum is becoming difficult 
due the appearance of drug-resistant parasite 
strains.4
Various measures to control malaria have 
reduced the number of yearly infections5 but 
mortality and morbidity remain high. The 
development of a malaria vaccine remains a 
global priority. Most of the tested vaccine 
candidates contain attenuated or killed 
parasites, or protein subunits that target the pre-
erythrocytic stage, blood stage or the 
transmission stage of the parasite.5 However, 
these vaccine candidates have failed and a 
vaccine with high efficacy is still required to 
combat and control this disease. 
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2An anti-toxin vaccine represents an alternative 
approach to target malarial pathogenesis in 
humans.6 Glycosylphosphatidylinositol (GPI), a 
glycolipid ubiquitous in eukaryotes, has been 
proposed as a prominent toxin in malaria that 
can be used for the development of a vaccine.7 
The glycan of GPIs exits in two forms, with and 
without the Man-IV unit, and is highly conserved 
across the different species of Plasmodium. 
Whereas GPIs lacking the Man-IV are mostly 
found as free glycolipids on the parasite 
membrane, GPIs containing this unit anchor 
proteins to the cell membrane. P. falciparum 
GPIs (PfGPIs) constitute up to 90% of the protein 
glycosylation on the parasite membrane,8,9 are 
synthesized during the entire life cycle and their 
biosynthesis is an important process for the 
development and survival of the parasites.10
During malaria infection, PfGPIs activate and 
induce the production of the pro-inflammatory 
cytokines TNF-α and IL-1 in macrophages.11 
Furthermore, anti-GPI antibodies are present in 
sera of malaria patients from endemic areas,12,13 
and the toxic activity of GPIs released into the 
bloodstream during infection can be blocked 
using GPI-mediated signaling and monoclonal 
antibodies.14 Thus, there is a growing interest in 
understanding the role of PfGPIs and their 
modifications as a basis to develop GPI 
derivatives as vaccine candidates against 
malaria.
Isolated GPIs have been used to study the anti-
GPI antibody response in malaria but the results 
from these studies cannot be used to establish a 
relationship between GPI structure, host anti-
GPI IgG response and infection.13,15-19,12 Some 
reports describe the GPI glycan as the dominant 
glycolipid epitope; others propose the lipid part 
as the dominant epitope in the immunogenic 
activity of the glycolipid.18,19,12 These 
discrepancies can be attributed to the difference 
in the composition and purity of the isolated 
glycolipids. To investigate the role of the GPI 
glycan, a series of GPI glycan fragments was 
synthesized, printed on microarrays, and used to 
analyze the specificity of anti-GPI antibodies 
recognizing the synthetic glycans.20 This study 
showed differences in antibody recognition 
depending on glycan size and composition. 
However, there is still limited insight into the role 
of the GPI glycan modifications and the 
immunogenicity of the PfGPI glycans.
Here, a series of GPI-fragments resembling the 
two main PfGPIs was synthesized to evaluate 
the role of myo-inositol, phosphoethanolamine 
and the Man-IV elogantion concerning 
immunogenicity and protection from CM. 
Glycoconjugates were created by coupling 
synthetic GPI glycans to the commonly used 
carrier protein CRM197 and used to evaluate the 
production of anti-glycan antibodies, T cell 
activation and protection of mice from challenge 
with Plasmodium berghei ANKA (PbA), an 
experimental cerebral malaria (ECM) model.
 Results and Discussion
Design of GPI glycan fragments. Six GPI 



















































































































































































































Merozoite Surface Proteins (MSPs) 
MSP-1, -2, -4, -5 and -10
Apical sushi protein (ASP) 







Figure 1. GPI of Plasmodium falciparum: a) Structure of the natural GPIs, Man-IV is found in combination with 
a protein attached, b) Synthetic PfGPI glycan fragments for conjugation to the CRM carrier protein and for 
immunization studies.
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3immunogenicity of the natural PfGPI glycan 
specific modifications, a PEtN unit at Man-III, a 
myo-inositol and an 1-2-mannose (Man-IV) 
attached to Man-III (Figure 1a). All fragments 
were designed with a thiol-linker for conjugation 
to the CRM197 carrier protein keeping the amine 
group of the PEtN moiety unmodified.21-23 The 
linker was attached either at the reducing end of 
the glycan or as part of a phosphodiester linked 
at the 1-O position of myo-inositol to maintain the 
natural orientation of the GPI. The fragments 1 - 
4 all lack the myo-inositol unit while fragments 1 
and 3 in addition lack the PEtN unit at Man-III. 
Fragment 5 carries a PEtN attached at Man-II to 
evaluate the role of the phosphorylation and 
glycan 6 containing the complete GPI structure 
was used as a reference (Figure 1b).
Synthesis and conjugation of GPI glycans. 
GPI glycan fragments 1 - 6 were synthesized by 
a convergent strategy using a x+2, x = 2, 3 or 4 
glycosylation strategy and a set of building 
blocks and protocols that we had established 
previously (Schemes S1 – S5, SI).24,25 Upon 
assembly of the fully protected glycan, fragments 
2, 4, 5 and 6 were phosphorylated using 
phosphitylation with H-phosphonates followed 
by oxidation. The final deprotection of all glycans 
was achieved by Birch reduction. The products 
were obtained after SEC purification in 57- 75% 
yield (for further details see the SI). 
The GPI fragments 1 - 6 were conjugated to the 
CRM197 carrier protein, a non-toxic variant of 
diphtheria toxin,26 to obtain the corresponding 
glycoconjugates (CRM-GPIs) CRM-1 - CRM-6. 
MALDI-TOF MS analysis of the glycoconjugates 
showed that between five and nine glycan units 
were coupled per protein, corresponding to a 
glycan content of 6 – 14% (Figure S3, SI). SDS-
PAGE and western blot analysis using 
biotinylated concanavalin A for detection 
confirmed glycoconjugate formation. In addition 
to a main band, corresponding to the monomeric 
form of the CRM, a glycoconjugate dimer and 
trimer were also detected (Figure 2c and SI). A 
galactose-CRM glycoconjugate (CRMGal) was 
prepared as a negative control for the 
immunization experiments. Analysis by CD of 
conjugates CRM-5, CRM-Gal and a comparison 
with the CD spectrum of CRM27 showed no effect 
of the conjugation process on the global 
structure of the protein (Figure S4).
Anti-GPI antibody response and cross-
reactivity. CRM-GPI glycoconjugates CRM-2, 
CRM-4, CRM-5 and CRM-6 were highly 
immunogenic in mice and induced a significant 
titer of anti-GPI IgG antibodies compared to 
control mice (Figure 3). In contrast, no induction 
or a very low antibody response were observed 
against glycoconjugates lacking PEtN and myo-
inositol, CRM-1 and CRM-3, respectively (Figure 
3a). The glycoconjugates of glycans containing 
trimannose and PEtN (CRM-2 and CRM-5) 
induced a marked increase in anti-glycan 
antibodies after prime-immunization (day 14), 
whereas glycoconjugates having a 
Figure 2. Synthesis and characterization of CRM glycoconjugates. Reagents and conditions: a) SBAP, 0.1 M 
NaPi pH 7.4, rt; b) GPIX, 0.1 M NaPi pH 8.0, 1 mM EDTA, rt; c) L-cysteine, 0.1 M NaPi pH 8.0, 1 mM EDTA, rt. b) 
MALDI-TOF analysis of CRM-5; c) SDS-PAGE and western blot analysis of CRM-5, d) Immunization protocol used 
in the murine Plasmodium berghei ANKA model.
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4tetramannose CRM-4 and CRM-6 induced 
significant anti-GPI antibody levels only after the 
first boost on day 28. The highest antibody titer 
after the second boost was observed in mice 
immunized with CRM-5. Interestingly, the 
antibody levels dropped for all groups after 
infection, except for the group that had received 
CRM-6. This reduction of antibody levels is 
either a result of parasite-induced immune 
suppression or binding of anti-GPI antibodies to 
naturally occurring GPIs after PbA infection.
The anti-glycan IgG antibody levels after the  
second boost on day 42 revealed a significant 
increase in antibody levels against 
glycoconjugates CRM-2, CRM-4, CRM-5 and 
CRM-6 compared to the CRM-Gal control 
(Figure 3c). However, on day 42 no significant 
difference in the anti-GPI IgM levels was 
detected between mice immunized with the 
glycocojugates and the controls (Figure 3b), 
showing a complete isotype switch from early 
IgM to IgG antibodies. Antibody isotype analysis 
of the subclasses IgG1, IgG2, and IgG3 was 
performed using a pool of sera from five mice per 
group. Binding of anti-glycan IgG1 and IgG2 
antibodies to respective fragments revealed 
similar patterns as described above. In contrast, 
sera of mice immunized with CRM-3 displayed a 
significant increase in antibody binding 
compared to control mice (Figure S8). Anti-
glycan IgG3 antibody levels that play an 
important role in anti-polysaccharide antibody 
responses in mice28,29 were drastically increased 
for CRM-5, and only marginally increased for 
CRM-2 and CRM-4 (Figure S8). Cross-reactivity 
of the anti-GPI antibodies against fragments 1-6 
was observed across all compounds with distinct 
characteristics (Figures S5 and S6). Control 
mice immunized with CRM-Gal did not develop 
cross-reacting antibodies against GPI 
fragments, but did against galactose (Figure S6). 
Glycoconjugates CRM-1 and CRM-3 (without 
PEtN and inositol) induced cross-reacting 
antibodies that exhibited binding to fragments 2-
4, whereas no reactivity was detected against 
the inositol containing fragments 5 and 6. Mice 
immunized with CRM-2 and CRM-4  developed 
predominantly cross-reacting antibodies against 
PEtN-containing glycans 2 and 4, but notably 
less against the inositol-containing fragments 5 
and 6, that also contain PEtN. By contrast, the 
glycoconjugates CRM-5 and CRM-6, containing 
both PEtN and inositol, induced cross-reacting 
antibodies with high binding of fragments 5 and 
6, moderate binding PEtN containing fragments 
2 and 4, and no detectable reactivity against 1 
and 3 To test the specifictiy of the antibodies  
against PEtN, we synthesized Gal-PEtN and 
evaluated the binding of antibodies to this 
structure. Sera of groups CRM-1 did not show 
binding. However, antibodies from CRM-Gal 
Figure 3. Anti-GPI antibody responses for mice immunized with the glycoconjugates. (a) Statistical 
significance was determined using two-way ANOVA to compare anti-GPI antibody levels between groups. PI = 
post infection. Endpoint anti-GPI Serum IgM (b) and IgG (c) antibodies after 2nd boost (day 42) against CRM and 
glycans 1-6.  (d) IgG3 antibody levels. Data shown as triplicates with mean of 1:50 diluted and pooled serum from 
5 mice/group. Statistical significance was determined using Student’s t-test, statistical significance shown by 
asterisks: ns=not significant, *(p<0.05), **(p < 0.01), ***(p < 0.001) and ****(p < 0.0001). MFI = mean fluorescence 
intensity.
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5bind moderately and the antibodies of CRM-2, -
4 and -5 showed high binding (Figure S9).
Protection against ECM. All CRM-GPI 
immunized mice except for CRM-5 displayed a 
CM incidence that was not significantly different 
from the control group. However, CRM-5 
induced a significant protection from cerebral 
malaria with a survival rate of 40%. Mice 
immunized with CRM-2, 4, 5 and 6 displayed 
increased levels of anti-GPI antibodies 
compared to the control group (Figure 4a). 
Protection in 30% of the animals was observed 
in the group immunized with CRM-1, having the 
lower glycan loading and antibody response; 
however, values did not reach statistical 
significance. CRM-5 immunized mice displayed 
a lower level of serum IFN- and did not develop 
a significant increase in TNF- level post-
infection, in contrast to mice immunized with 
other GPI glycoconjugates (see below). This 
reduction in pro-inflammatory cytokine 
production can explain the ameliorated clinical 
symptoms of mice immunized with CRM-5.
Vaccine-specific T-cell response. An 
immunological characterization of five mice per 
group, sacrificed on day 6 post-infection, was 
performed to determine spleen cell populations, 
brain T cell sequestration, and serum cytokine 
levels. CRM and CRM-GPIs specific T cell 
response  was analyzed determining IFN-γ 
production by isolated splenocytes upon re-
stimulation with the correponding 
glycoconjugate used for immunization. ELISpot 
analysis showed baseline frequencies of CRM-
specific IFN-γ+ T cells in all immunized animals. 
A significant increase in T cell activation of CRM-
GPIs re-stimulated splenocytes was observed in 
all groups. Interestingly, this increase was also 
observed in cells of CRM-Gal immunized mice, 
suggesting more efficient uptake of CRM-GPIs 
and CRM-Gal into antigen-presenting cells than 
of CRM alone and an enhanced subsequent 
MHC-II presentation of CRM-derived peptides 
(Figure 4b).30 No difference in the number of 
IFN-γ spot forming units (SFU) was detected 
between mice immunized with either CRM-Gal 
or CRM-GPIs (Figure 4b).
Spleen cell composition. Spleen cells were 
isolated on day 6 post-infection. Analysis of T 
cell frequency in spleen and T cell activation in 
CRM-GPIs immunized and PbA-challenged 
mice revealed a lymphopenia for CD4+ but not 
for CD8+ T cells (Figure S10). Early leukopenia, 
particularly for CD4+ T cells, is a well-known 
phenomenon during malaria. T cell activation, as 
defined by expression of the early activation 
marker CD69, was however higher in both CD4+ 
Figure 4. Protection from ECM and cellular immune response in immunized mice. (a) Mice immunized with 
GPI conjugates survived longer than control mice immunized with CRM-Gal. Mice were euthanized at an early 
stage of ECM to minimize suffering. (b) IFN-γ production by T-cells upon re-stimulation of spleen cells by their 
immunized CRM-GPI conjugate or CRM alone. (c) Frequencies of regulatory T-cells in all challenged groups were 
compared to the non-infected control group. Serum levels of pro-inflammatory cytokines TNF- (d) and IL-6 (e) 
determined pre- and post- PbA infection (day 42 and 48) using cytometric bead array. Data is shown as mean ± 
SEM. Statistical significance was determined using Student’s t-test, statistical significance is shown by asterisks: 
*(p < 0.05), **(p < 0.01), ***(p < 0.001), SFU = spot forming unit.
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6and CD8+ T cells compared to non-infected 
controls. Interestingly, CD4+ and CD8+ T cell 
activation was slightly decreased in CRM-5 and 
CRM-3 immunized mice, as would be expected 
considering the lower level of pro-inflammatory 
serum cytokines detected in these groups.
The proportion of regulatory T cells (Treg), 
measured by intracellular staining of the Treg-
specific transcription factor FoxP3, was 
significantly increased in all PbA-challenged 
groups compared to the non-infected control 
group (Figure 4c). No significant difference was 
observed between CRM-Gal and CRM-GPIs 
immunized mice, suggesting that glycan 
antitoxic vaccination does not markedly impact 
regulatory T cell frequency.
P. berghei ANKA challenge was accompanied 
by an activation of macrophages and dendritic 
cells in all groups as indicated by an increased 
expression of the co-stimulatory molecule CD80 
on CD11b+ cells (mainly macrophages) and 
CD11c+ cells (mainly dendritic cells) (data not 
shown).
Serum cytokine levels. CRM-GPIs immunized 
and control mice displayed low or only 
background levels of IFN-γ, TNF-α and IL-6 after 
the second boost vaccination (Figure 4 and S6). 
To investigate whether the glycoconjugates’ 
immunizations modified the pro-inflammatory 
cytokine responses during PbA infection, serum 
cytokines of mice were further analyzed on day 
48 (day 6 p.i.). Generally, PbA infected groups 
displayed significantly increased levels of IFN-γ, 
TNF-α and IL-6 after challenge (Figure 4d and 
4e). TNF-α was not significantly increased in 
CRM-1 and CRM-5 immunized mice, and 
observed at a similar level as for conjugates 
CRM-3 and CRM-4. The level of pro-
inflammatory cytokines post infection varied 
between CRM-GPIs vaccinated mice. While 
mice immunized with CRM-6 showed 
consistently increased levels of IFN-γ, TNF-α 
and IL-6, those were considerably reduced for 
mice immunized with CRM-5. However, no 
significant difference in cytokine levels was seen 
in CRM-GPIs immunized versus CRM-Gal 
control mice. Analysis of serum cytokines 
revealed that CRM-GPIs did not induce an 
unspecific inflammatory response. Serum TNF-
α and IFN-γ levels were correlated with ECM and 
CM susceptibility. Interestingly, CRM-5 
immunized mice did not develop a significant 
increase in TNF-α level and displayed a lower 
level of serum IFN-γ, which is in accordance with 
the reduced incidence of CM in this group. 
 Discussion
Based on previous reports describing the toxicity 
of GPIs, their role in CM and the interaction of 
isolated and synthetic GPIs with antibodies in 
sera of infected patients from endemic areas,15,20 
a library of six GPI glycan fragments were used 
to evaluate the role of the phosphoethanolamine 
(PEtN), the myo-inositol and the mannose at the 
non-reducing end (Man-IV) of the GPI glycan in 
the immune protection of mice in a murine 
malaria model. Fragments 1-6 were synthesized 
and conjugated to the carrier protein CRM197. 
These CRM glycoconjugates were used to 
immunize mice in the presence of Alum as 
adjuvant, commonly used in glycoconjugate 
vaccines31,32, before mice were challenged with 
P. berghei ANKA.
Determination of the anti-glycan antibodies 
using microarrays showed that all CRM-GPI 
glycoconjugates in this study were immunogenic 
and induced the production of anti-glycan 
antibodies. Conjugates of glycans having only 
mannose and glucosamine, CRM-1 and CRM-3, 
were less immunogenic than glycoconjugates 
containing PEtN and myo-inositol. A cross-
reactivity microarray analysis revealed that the 
length of the mannose backbone is important for 
immune recognition. While the conjugate of 
GPI1 having only Man3 was not detected by 
antibodies, CRM-3 carrying glycans with the 
Man-IV unit was more immunogenic and was 
detected by cross-reacting antibodies from 
CRM-1 immunized mice. This observation is in 
line with previous findings on human anti-GPI 
antibody binding, where glycan fragments 
containing fewer than five carbohydrate units 
were not recognized.20 In contrast to human sera 
that showed a slight difference in antibody 
recognition toward GPIs with or without a PEtN 
unit,20 PEtN was also detected as an important 
immunogenic epitope in mice. Substantial 
differences were observed in this study between 
glycoconjugates having identical glycans with or 
without PEtN (CRM-1 vs CRM-2 and CRM-3 vs 
CRM-4, Figure 3). This observation was 
confirmed by binding of antibodies from CRM-2, 
-4  and -5 to Gal-PEtN, which was not observed 
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7for antibodies from CRM-1. Noteworthy, and in 
agreement with previous reports,33 inositol was 
also an immunogenic epitope in the glycans, 
which was observed in the immune response to 
CRM-5 and CRM-6. 
IgG subclass analysis further revealed unique 
findings for the most protective glycoconjugate 
vaccine in this study. In agreement with previous 
studies on immunoglobulin subclasses against 
naturally occurring Plasmodium GPIs,34 the IgG3 
subclass was highly abundant in mice 
immunized with CRM-5, but not in mice 
immunized with other glycoconjugates (Figure 
3d). Since IgG1 and IgG3 share the highest 
affinity for Fc receptors on phagocytic cells, high 
titers of these IgG subclasses might have 
facilitated efficient GPI clearance post-infection. 
However, the reason of the sharp increase in 
IgG3 for CRM-5 needs to be further elucidated.
Mice immunized with the conjugates CRM-1, 
CRM-2 and CRM-5, containing the Man3-GlcN 
moiety, revealed higher resistance to ECM 
compared to the fragments containing the Man4-
GlcN moiety, CRM-3, CRM-4 and CRM-6, which 
is the main structure found on the structures of 
GPI-modified proteins attached to the surface of 
P. falciparum.35 GPIs containing only three 
mannoses exist mostly in free GPIs that are five 
times more abundant than GPI anchoring 
proteins.33,36 All GPI fragments were conjugated 
to CRM via the glucosamine or myo-inositol unit 
to retain the GPIs’ natural orientation within the 
cell membrane. This type of conjugation was 
selected to improve the presentation of the PEtN 
unit, which plays an important role in the 
production of antibodies and protection against 
ECM. The higher protective potential of NEtP-
Man3-GlcN-containing fragments compared to 
NEtP-Man4-GlcN-containing fragments could 
have been influenced by a lack of protein 
attached to the PEtN unit, which may cause a 
different presentation of the four mannoses, thus 
reducing the immunogenicity of the Man4-GPI. 
This observation is confirmed by the results for 
CRM-6 and previous studies using a similar 
glycan conjugated to KLH via the PEtN on Man-
III that protected mice from cerebral pathology.7 
Although the change from KLH to CRM for 
conjugation and from Freund’s adjuvant to Alum 
may have contributed to the generally lower 
protection observed in this study, the results 
here provide evidence that the site of 
conjugation and the GPI-glycan structure should 
be carefully considered. Accordingly, structures 
containing the free NEtP-Man3-GlcN epitope or 
a protein bound NEtP-Man4-GlcN may influence 
vaccine efficacy.
Furthermore, this study demonstrates that 
immunogenicity varies according to the 
composition of GPI structures. Mice immunized 
with CRM-5 exhibited a slightly reduced 
activation of CD4+ and CD8+ T cells, 
accompanied by decreased levels of the pro-
inflammatory cytokines IFN-γ and TNF-α. 
Immunization with other CRM-GPI conjugates 
did not affect the cellular or humoral immune 
response in a similar manner. Cytokine levels in 
fact may have influenced CD8+ T cell 
sequestration in the brain, thus impacting ECM 
development. These observations correlate with 
the enhanced survival rate of mice immunized 
with CRM-5.
 Conclusion
A series of PfGPI fragments were synthesized, 
conjugated to the CRM-197 carrier protein, and 
used to perform a structure-activity relationship 
study with regard to immunogenicity and 
protection against experimental cerebral malaria 
(ECM) in mice. Moderate differences in cerebral 
pathology between mice immunized with the 
different CRM-GPI glycoconjugates were 
observed that depended on the number of 
mannoses (Man3>Man4) and the presence of 
PEtN and myo-inositol units on the glycans. The 
highest protection (40%) was observed in mice 
immunized with CRM-5, a glycoconjugate 
containing the GPI glycan core with the PEtN at 
a non-natural position. Although protection can 
be partially attributed to antibody responses 
against CRM-5, alterations in T cell activation as 
well as the level of pro-inflammatory cytokines 
may also have affected ECM susceptibility. 
Material and Methods 
Chemical synthesis of GPI fragments. All 
glycans were synthesized from protected 
building blocks using established solution-phase 
protocols, as described in Supplementary 
Methods.
Conjugation of Fragments 1-6 to CRM-197 
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8CRM carrier protein was purchased from Pfēnex 
Inc., 1 M solution of resin-bound TCEP was 
purchased from Thermo Scientific and 
autoclaved sterile water was used for the 
conjugation. 250 µL of TCEP resin solution was 
centrifuged for 3 mins and excess of water was 
removed. TCEP resin was resuspended in 150 
µL of 0.1 M sodium phosphate buffer pH 8.0 and 
centrifuged for 3 min. The excess buffer was 
removed and autoclaved water was added. The 
GPI fragment was dissolved in 120 µL water, 
transferred to the TCEP solution and incubated 
at rt. After 1 h, TCEP resin was filtered off using 
a syringe and washed with autoclaved water 
(5x50 µL). All water fractions were then 
combined and lyophilized. The reduction of the 
disulfide was confirmed by LC-MS. 
A solution of SBAP (1.58 mg) in DMF (60 µL) 
was added to a stirred solution of CRM (3 mg) in 
0.1 M sodium phosphate buffer pH 7.4 at rt. The 
reaction mixture was stirred for 1 h, the solution 
was concentrated to 250 μL using an Amicon® 
Ultra-4 centrifugal filter tube (10 kDa cut-off, 
Millipore) and was washed with water (4 x 1 mL) 
and with 0.1 M sodium phosphate buffer pH 8.0 
(1x 1 mL). Finally, the activated CRM was 
concentrated to obtain around 100 μL of 
solution. The solution of activated CRM was 
added to the reduced fragment and the mixture 
was stirred overnight at rt. Then, the solution was 
concentrated to 250 μL of volume using an 
Amicon® Ultra-4 Centrifugal tube (10 kDa cut off, 
Millipore), and washed with water (4x 1 mL) and 
with 0.1 M sodium phosphate buffer (pH 8.0) to 
obtain 250 μL of the CRM-GPI glycoconjugate 
solution. Cysteine (0.94 mg) was added directly 
to the solution in the centricon and incubated for 
1 h at rt. Then, the mixture was washed with 
water (4x 1 mL) and with PBS buffer to obtain the 
desired CRM-GPI glycoconjugate. 
Characterization of conjugates
All protein intermediates and the final CRM-GPI 
glycoconjugates were characterized by MALDI-
TOF mass spectrometry and by gel 
electrophoresis. SDS-PAGE gels were directly 
stained with Coomassie Brilliant Blue R250 
(CBB) (Sigma-Aldrich, Munich, Germany, 6104-
59-2) or used for western blotting. For gel 
electrophoresis, glycoconjugates were diluted 
1:10 in sterile water, loading buffer was added, 
boiled for 5 minutes and loaded onto a 12% 
polyacrylamide gel. Gel electrophoresis was 
performed at 150 V, 150 mA for 60 minutes. 
Western blot transfer was accomplished at 100 
V and 35 mA. The membrane was routinely 
tested for protein transfer with Ponceau S 
(Sigma-Aldrich, Munich, Germany, 6226-79-5), 
subsequently blocked for 2 h with 5% BSA in 
PBS-T at rt. Biotinylated Concanavalin-A (Vector 
Laboratories, Burlingame, California, B-1005) 
was diluted 1:500 in 1x PBS containing 5% BSA, 
0.01mM Mn2+ and 0.1mM Ca2+ and incubated at 
rt for 2 h under shaking. The membrane was 
subsequently washed and streptavidin HRP (BD 
Pharmingen, Heidelberg, Germany, 557630) 
was added 1:500 in 1x PBS 5% BSA 0.01mM 
Mn2+ 0.1mM Ca2+ and incubated for 1 h at rt. 
Finally, the membrane was washed again in 1x 
PBS 0.01mM Mn2+ 0.1mM Ca2+ and developed 
by enhanced luminol-based chemiluminescence 
according to manufacturer’s instructions 
(Thermo Fisher Scientific, Darmstadt, Germany, 
32109). Dual color precision protein standard 
(Bio-Rad Laboratories, Munich, Germany, 161-
0374) was used as protein standard. CD spectra 
of CRM-5 and CRM-Gal were recorded on a 
Applied Photophysics ChirascanTM 
spectrophotometer using a 0.3-0.5 mg/mL in 
PBS buffer. Spectra were recorded between 190 
and 260 nm, at 25°C and using PBS buffer as 
reference.
Animal experiments 
Animals were treated strictly according to 
German and European Law (Directive 
2010/63/EU). Recommendations of the Society 
for Laboratory Animal Science (GV-SOLAS) and 
of the Federation of European Laboratory 
Animal Science Associations (FELASA) were 
followed. The Office for Health and Social Affairs 
Berlin (LAGeSo) approved the experiment 
(Permit Number: G0239/14). All efforts were 
made to minimize suffering. 
All C57BL/6JRj mice used in this study were 
obtained from Janvier Labs (Saint-Berthevin, 
France). Mice were housed in individually-
ventilated cages (IVCs) under specific pathogen 
free (SPF) conditions in the animal facility of the 
Federal Institute for Risk Assessment (BfR, 
Berlin, Germany). Mice were provided food and 
water ad libitum. Upon delivery (day -7), mice 
were allowed to rest for one week before 
experimental setting was started. 
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9Immunization and challenge experiment in 
C57BL/6JRj mice. 
C57BL/6JRj mice were grouped into groups of 
15 animals: Mice were vaccinated 
intraperitoneally (i.p.) on day 0, 14 and 28. Study 
groups were immunized with CRM-GPIs and 
control mice were immunized with CRM-Gal. 
Galactose conjugated CRM was used as a 
control to account for possible conformational 
changes of the glycan-loaded carrier protein that 
has been described previously.37 Serum was 
obtained at 14-day intervals: prior prime, 1st and 
2nd boost-vaccination, and post infection. All 
mice were challenged on day 42 with 1x106 PbA 
infected erythrocytes i.p. On day 6 post-infection, 
five mice per group were sacrificed for the 
immunological characterization, consisting of 
spleen cell composition, brain T cell 
sequestration, and carrier protein-specific T cell 
re-stimulation. The remaining ten mice per group 
were used to assess ECM incidence as a read-
out of vaccine efficacy. Group sizes of ten mice 
for vaccine efficacy studies were based on the 
expected incidence of ECM in C57BL/6 mice 
between 80-100%. The dependent variable 
(survival) in this group was analyzed using a log-
rank test.
Immunization 
On day 0, 5-week-old female C57BL/6JRj mice 
were prime-immunized i.p. with CRM-GPIs 
glycoconjugates or CRM-Gal as a control. Two 
boost-immunizations were performed at 14-day 
intervals (day 14 and day 28).  Each mouse was 
injected a total of 100 μL i.p. of either CRM-GPI 
glycoconjugate or CRM-Gal formulated with 
aluminum hydroxide (Alum). Immunizations 
were performed using 5 μg of glycan per 
vaccination. Due to diverging loadings of glycans 
on CRM, conjugates were diluted in sterile PBS 
accordingly. CRM-GPIs glycoconjugates were 
formulated with aluminum hydroxide 1:2 
(Alhydrogel®, Brenntag, Denmark) and rotated 
overnight at 4 °C before immunization.54
Serum collection
Blood was taken from each mouse before the 
prime-immunization, first and second boost, and 
PbA infection (days 0, 14, 28, 42). Blood was 
allowed to coagulate for at least 30 minutes at rt 
and was centrifuged at 2000 x g for 15 minutes. 
Isolated serum was stored at -80 °C until further 
use. 
Plasmodium berghei ANKA infection
Mice were infected with Plasmodium berghei 
ANKA MRA-671 stabilates (stocks obtained from 
the Malaria Research and Reference Reagent 
Resource Center, Manassas, VA, USA). Frozen 
stabilates (2x107 infected RBCs, stored in liquid 
nitrogen in a solution of 0.9% NaCl, 4.6% 
sorbitol, and 35% glycerol) were quickly thawed 
by hand and carefully re-suspended in sterile 
PBS. Ten mice were infected intraperitoneally 
with one stabilate in 100 μL RBCs suspension, 
corresponding to 1x106 infected RBCs. Mice 
were randomized prior to infection. It has 
consistently been shown that C57BL/6JRj mice 
infected with P. berghei ANKA develop 
neurological symptoms from day 6 on. Hence, all 
mice were monitored repeatedly daily for early 
signs of ECM according to a pre-defined scoring 
system (Permit Number: G0239/14). In 
accordance with the animal study proposal, mice 
scoring ≥3 on this pre-defined system or a weight 
loss of ≥20% were humanely euthanized. All 
surviving mice were euthanized 12 days post-
infection (day 54).
Glycan array printing and development 
Solutions of the GPI fragments 1 - 6 were diluted 
to 1 mM and 0.2 mM using PBS 0.1X pH 7.4. 
Galactose, CRM, BSA-spacer, buffer and S. 
pneumoniae polysaccharide were further added 
as controls. 25 mM and 5 mM TCEP (pH 8) were 
added to the glycan and protein  solutions 20 
minutes prior to printing. Glycans and proteins 
were printed on maleimide slides (PolyAn, 
Berlin, Germany) using a SciFlexarrayer 
microarray printer (Scienion, Berlin, Germany) in 
triplicates in a 64-well format. Following 24 h 
incubation in a wet chamber at rt, slides were 
quenched for 1 h with 0.1% (v/v) 2-
mercaptoethanol in PBS at rt. Slides were 
washed with water, dried and stored in a 
desiccator until used. 
Anti-GPI antibody levels in CRM-GPI immunized 
and control mice were measured on days 0, 14, 
28, 42 and on day 6 post infection. Printed slides 
were blocked with 1% BSA in 1x PBS for 1 h at 
rt, washed with water, and dried. Serum dilutions 
(1:50) were added to the corresponding well and 
the slides were incubated at 4 °C in a wet 
Page 9 of 13































































chamber overnight. Following incubation, serum 
was discarded and wells washed three times 
with 1x PBS 0.1 % Tween. 23 μL of the following 
anti-mouse IgG or IgM antibody dilutions were 
added and incubated 1 h at rt in a dark wet 
chamber: Rabbit anti-mouse IgG-FITC (diluted 
1:400) (Sigma-Aldrich, Munich, Germany, 
F9137); Donkey anti-mouse IgM-Alexa Fluor® 
594 (1:200) (Dianova, Hamburg, Germany, 715-
585-020); Goat anti-mouse IgG1-AlexaFluor® 
594 (1:400) (Thermo Fischer Scientific, 
Darmstadt, Germany, A21125); Goat anti-
mouse IgG2-AlexaFluor® 647 (1:200) (Thermo 
Fischer Scientific, Darmstadt, Germany, 
A21241); Goat anti-mouse IgG3-AlexaFluor® 
488 (1:200) (Thermo Fischer Scientific, 
Darmstadt, Germany, A21151); and Goat anti 
rabbit IgG-FITC (1:400) (Dianova, Hamburg, 
Germany, ab6717). Slides were washed three 
times with PBS 0.1% Tween, rinsed carefully 
with water, dried, and measured by Axon 
GenePix® 4300A fluorescent scanner 
(Molecular Devices, Sunnyvale, CA, US). The 
values used for analysis correspond to the 
average of the mean fluorescent intensities after 
background subtraction of triplicates.
Statistical analysis. Statistical analysis was 
performed using the GraphPad Prism software 
(GraphPad Software Inc., La Jolla, CA, US). 
Unpaired Student’s t test was used to compare 
different sets of data, whereas two-way ANOVA 
was used to compare anti-glycan antibody levels 
over time between immunized and non-
immunized groups. Log rank test was employed 
for analysis of survival between different groups. 
Statistical significance within figures is shown by 
asterisks: * represents p < 0.05, ** p < 0.01, *** 
p < 0.001 and **** p < 0.0001.
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